These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 16257840)

  • 1. The significance of tumor heterogeneity for prediction of DNA ploidy of prostate cancer.
    Häggarth L; Auer G; Busch C; Norberg M; Häggman M; Egevad L
    Scand J Urol Nephrol; 2005; 39(5):387-92. PubMed ID: 16257840
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Conventional assessment of needle biopsy specimens is more useful than digital image analysis of proliferation and DNA ploidy in prediction of positive surgical margins at radical prostatectomy.
    Sengupta S; Cheville JC; Lohse CM; Zincke H; Myers RP; Riehle DL; Pankratz VS; Blute ML; Sebo TJ
    Urology; 2006 Jul; 68(1):94-8. PubMed ID: 16844452
    [TBL] [Abstract][Full Text] [Related]  

  • 3. DNA ploidy and proliferation heterogeneity in human prostate cancers.
    Shankey TV; Jin JK; Dougherty S; Flanigan RC; Graham S; Pyle JM
    Cytometry; 1995 Sep; 21(1):30-9. PubMed ID: 8529468
    [TBL] [Abstract][Full Text] [Related]  

  • 4. DNA image cytometry of prostatic carcinoma: a comparison of needle core biopsy and subsequent prostatectomy specimens.
    Leung CS; Zbieranowski I; Demers J; Murray D
    Mod Pathol; 1994 Feb; 7(2):195-9. PubMed ID: 8008743
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Deoxyribonucleic acid ploidy status as no basis for pathologic stage prediction in clinically resectable prostate cancer.
    Egawa S; Satoh T; Iwamura M; Aihara M; Kuwao S; Uchida T; Koshiba K
    Urology; 1996 Apr; 47(4):548-52. PubMed ID: 8638366
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Flow cytometry in prostate cancer. Evaluation of its feasibility for biopsy specimens and correlation with grading].
    Ferrara G; Monaco R; Capasso A; Bellomo PF; Fruttero A; Pugno F; Nappi O; Ruà S
    Pathologica; 1998 Feb; 90(1):14-9. PubMed ID: 9628974
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Needle biopsy DNA ploidy status predicts grade shifting in prostate cancer.
    Ross JS; Sheehan CE; Ambros RA; Nazeer T; Jennings TA; Kaufman RP; Fisher HA; Rifkin MD; Kallakury BV
    Am J Surg Pathol; 1999 Mar; 23(3):296-301. PubMed ID: 10078920
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prediction of pathologic stage and postprostatectomy disease recurrence by DNA ploidy analysis of initial needle biopsy specimens of prostate cancer.
    Ross JS; Figge H; Bui HX; del Rosario AD; Jennings TA; Rifkin MD; Fisher HA
    Cancer; 1994 Nov; 74(10):2811-8. PubMed ID: 7954242
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Relationship between DNA ploidy, glandular differentiation, and tumor spread in human prostate cancer.
    Frankfurt OS; Chin JL; Englander LS; Greco WR; Pontes JE; Rustum YM
    Cancer Res; 1985 Mar; 45(3):1418-23. PubMed ID: 3971384
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Increasing the number of biopsies increases the concordance of Gleason scores of needle biopsies and prostatectomy specimens.
    Divrik RT; Eroglu A; Sahin A; Zorlu F; Ozen H
    Urol Oncol; 2007; 25(5):376-82. PubMed ID: 17826653
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prediction of percent Gleason grade 4/5 by multiple core biopsies.
    Glaessgen A; Busch C; Norberg M; Häggman M; Nilsson B; Egevad L
    Scand J Urol Nephrol; 2006; 40(6):465-71. PubMed ID: 17130098
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Potential markers of prostate cancer aggressiveness detected by fluorescence in situ hybridization in needle biopsies.
    Takahashi S; Qian J; Brown JA; Alcaraz A; Bostwick DG; Lieber MM; Jenkins RB
    Cancer Res; 1994 Jul; 54(13):3574-9. PubMed ID: 8012984
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Percentages of positive cores, cancer length and Gleason grade 4/5 cancer in systematic sextant biopsy are all predictive of adverse pathology and biochemical failure after radical prostatectomy.
    Suekane S; Noguchi M; Nakashima O; Yamada S; Kojiro M; Matsuoka K
    Int J Urol; 2007 Aug; 14(8):713-8. PubMed ID: 17681061
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intratumoral heterogeneity in colorectal carcinoma: trucut sampling for DNA ploidy analysis.
    Giovagnoli MR; Giarnieri E; Midiri G; Tesoriere A; Ferraro S; Vecchione A
    Anticancer Res; 1999; 19(5C):4577-80. PubMed ID: 10650813
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prediction of extracapsular extension of prostate cancer based on systematic core biopsies.
    Tarján M; Tot T
    Scand J Urol Nephrol; 2006; 40(6):459-64. PubMed ID: 17130097
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of patients with low-risk for aneuploidy: comparative discriminatory models using linear and machine-learning classifiers in prostate cancer.
    Venkataraman G; Heinze G; Holmes EW; Ananthanarayanan V; Bostwick DG; Paner GP; Bradford-De La garza CM; Brown HG; Flanigan RC; Wojcik EM
    Prostate; 2007 Oct; 67(14):1524-36. PubMed ID: 17683063
    [TBL] [Abstract][Full Text] [Related]  

  • 17. DNA ploidy by image analysis of individual foci of prostate cancer: a preliminary report.
    Greene DR; Taylor SR; Wheeler TM; Scardino PT
    Cancer Res; 1991 Aug; 51(15):4084-9. PubMed ID: 1855223
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The relationship between tumor volume and the number of positive cores in men undergoing multisite extended biopsy: implication for expectant management.
    Ochiai A; Troncoso P; Chen ME; Lloreta J; Babaian RJ
    J Urol; 2005 Dec; 174(6):2164-8, discussion 2168. PubMed ID: 16280756
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Heterogeneity in prostate cancer: prostate specific antigen (PSA) and DNA cytophotometry.
    Krause FS; Feil G; Bichler KH; Schrott KM; Akcetin ZY; Engehausen DG
    Anticancer Res; 2005; 25(3A):1783-5. PubMed ID: 16033100
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Percentage of cancer in prostate biopsies as prognostic factor for staging and postoperative biochemical failure after radical prostatectomy.
    Villamón-Fort R; Martínez-Jabaloyas JM; Soriano-Sarriá P; Ramos-Soler D; Pastor-Hernández F; Gil-Salom M
    Urol Int; 2007; 78(4):328-33. PubMed ID: 17495491
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.